{"id":6894,"date":"2021-03-17T12:21:04","date_gmt":"2021-03-17T19:21:04","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6894"},"modified":"2021-03-18T12:22:12","modified_gmt":"2021-03-18T19:22:12","slug":"efficacy-of-the-chadox1-ncov-19-covid-19-vaccine-against-the-b-1-351-variant","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/17\/efficacy-of-the-chadox1-ncov-19-covid-19-vaccine-against-the-b-1-351-variant\/","title":{"rendered":"Efficacy of the ChAdOx1 NCoV-19 Covid-19 Vaccine against the B.1.351 Variant"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Two doses of the Oxford-AstraZeneca (<\/span><span style=\"font-weight: 400\">ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 among people infected with the B.1.351 variant in a <\/span><span style=\"font-weight: 400\">multicenter randomized trial <\/span><span style=\"font-weight: 400\">in South Africa. Mild-to-moderate COVID-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9%. Among the 42 participants who developed COVID-19, 39 (92.9%) were infected with the B.1.351 variant. Vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4%. The authors note that the demographic profile of enrolled participants contributed to the lack of severe COVID-19, and therefore trial results are inconclusive regarding the vaccine\u2019s potential to protect against severe disease. <\/span><i><span style=\"font-weight: 400\">[EDITORIAL NOTE: A pre-print related to this manuscript was summarized on February 12, 2020]<\/span><\/i><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Madhi et al.\u00a0(Mar 16, 2021). Efficacy of the ChAdOx1 NCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2102214\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1056\/NEJMoa2102214<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 among people infected with the B.1.351 variant in a multicenter randomized trial in South Africa. Mild-to-moderate COVID-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9%. Among the&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/17\/efficacy-of-the-chadox1-ncov-19-covid-19-vaccine-against-the-b-1-351-variant\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33,141],"topic":[31],"class_list":["post-6894","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","tag-variant","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6894"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6894\/revisions"}],"predecessor-version":[{"id":6895,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6894\/revisions\/6895"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6894"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}